Male hypogonadism is a clinical syndrome characterized by inadequate testosterone production accompanied erotic by relevant symptoms such as reduced libido, fatigue, decreased muscle mass, infertility, and mood disturbances. It may be classified as primary (testicular failure), secondary (hypothalamic or pituitary dysfunction), or mixed.
Primary hypogonadism results from intrinsic testicular pathology, including genetic conditions such as Klinefelter syndrome, orchitis, chemotherapy exposure, or trauma. Secondary hypogonadism involves impaired gonadotropin secretion and may be associated with pituitary tumors, systemic illness, obesity, or chronic opioid use.
Diagnosis requires both clinical symptoms and biochemical confirmation through morning serum testosterone measurements. If low levels are detected, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) should be evaluated to distinguish primary from secondary causes.
Treatment strategies vary according to etiology and reproductive goals. Testosterone replacement therapy (TRT) can alleviate symptoms but may suppress spermatogenesis; thus, fertility-preserving alternatives such as selective estrogen receptor modulators or gonadotropin therapy may be preferred in younger men. Comprehensive evaluation is essential to balance symptomatic relief with long-term reproductive health.
Leave a Reply